Overview

A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
A Phase 1/2 dose escalation / dose expansion study of DSP 5336 in patients with relapsed or refractory AML.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sumitomo Dainippon Pharma Oncology, Inc
Treatments:
Antifungal Agents
Clotrimazole
Fluconazole
Miconazole
Posaconazole